NASDAQ:RGNXRegenxbio Stock Price, Forecast & News

Regenxbio's stock was trading at $32.89 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RGNX shares have increased by 21.5% and is now trading at $39.96. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Regenxbio.

Regenxbio is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Regenxbio.

Regenxbio Inc (NASDAQ:RGNX) announced its quarterly earnings data on Thursday, May, 7th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.87) by $0.21. The biotechnology company had revenue of $17.60 million for the quarter, compared to the consensus estimate of $17.99 million. Regenxbio had a negative return on equity of 27.84% and a negative net margin of 197.23%. The firm's revenue was up 1855.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.89) earnings per share. View Regenxbio's earnings history.

6 brokerages have issued 12-month price targets for Regenxbio's shares. Their forecasts range from $37.00 to $150.00. On average, they expect Regenxbio's share price to reach $68.33 in the next twelve months. This suggests a possible upside of 71.0% from the stock's current price. View analysts' price targets for Regenxbio.

Press coverage about RGNX stock has trended negative recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Regenxbio earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news about Regenxbio.

Some companies that are related to Regenxbio include Crispr Therapeutics (CRSP), Adaptive Biotechnologies (ADPT), Acceleron Pharma (XLRN), Allogene Therapeutics (ALLO), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), bluebird bio (BLUE), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Twist Bioscience (TWST) and Immunovant (IMVT). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Regenxbio investors own include NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Voyager Therapeutics (VYGR), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Amarin (AMRN), QUALCOMM (QCOM), Bristol-Myers Squibb (BMY) and Square (SQ).

Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."

Regenxbio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Exane Derivatives (0.01%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View institutional ownership trends for Regenxbio.

RGNX stock was bought by a variety of institutional investors in the last quarter, including Exane Derivatives. View insider buying and selling activity for Regenxbio.

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of RGNX stock can currently be purchased for approximately $39.96.

Regenxbio has a market capitalization of $1.49 billion and generates $35.23 million in revenue each year. The biotechnology company earns $-94,730,000.00 in net income (profit) each year or ($3.26) on an earnings per share basis. Regenxbio employs 192 workers across the globe.

The official website for Regenxbio is www.regenxbio.com.

Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]